약독 생 소아마비 백신 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 7.9%의 연평균 성장률로 27억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 백신의 안정성과 보존성 향상, 분쟁 지역의 소아마비 환자 부활, 박멸 활동의 기증자 피로, 정기 예방접종 프로그램 확대, 보다 안전한 약독성 생백신 균주의 연구 개발 증가 등에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 백신 유래 소아마비 바이러스의 출현, 새로운 경구용 소아마비 백신 개발, 백신 제제의 기술적 발전, 디지털 기술 통합, 민관 협력 강화 등을 꼽을 수 있습니다.
예방접종 프로그램의 확대는 향후 몇 년 동안 약독 생 소아마비 백신(LAPV) 시장의 성장에 크게 기여할 것으로 예상됩니다. 예방접종 프로그램은 전염병의 확산을 방지하기 위해 정부, 보건 기관 및 기타 기관이 백신을 사람들에게 배포하는 구조화된 노력입니다. 이러한 프로그램은 질병 예방의 중요성에 대한 전 세계적인 인식이 높아지고 정부, 국제보건기구 및 자금 지원 기관의 강력한 지원으로 인해 더욱 탄력을 받고 있습니다. 예방접종 프로그램은 LAPV의 광범위한 배포, 안전한 투여, 높은 접종률을 보장함으로써 LAPV를 지원하고 있으며, 이 모든 것이 집단 면역을 구축하고 바이러스 감염을 예방하며 세계 소아마비 퇴치 목표를 달성하는 데 도움이 되고 있습니다. 예를 들어, 2023년 10월 미국 질병예방통제센터(CDC)는 디프테리아, 파상풍, 백일해(DTP) 백신 첫 접종률이 2021년에서 2022년 사이에 전 세계적으로 86%에서 89%로 상승했다고 보고했습니다. 이에 따라 예방접종 프로그램의 확대는 약독 생 소아마비 백신의 시장 성장을 촉진할 것으로 예상됩니다.
약독 생 소아마비 백신 시장의 주요 업체들은 자사 백신이 세계 보건 당국이 정한 안전성과 유효성 기준을 충족하는지 확인하기 위해 규제 당국의 승인을 받는 데 주력하고 있습니다. 규제 당국의 승인은 특정 지역이나 국가에서 백신과 같은 제품의 마케팅, 판매 및 사용을 허용하는 정부 보건 기관 및 규제 당국의 공식적인 승인을 의미합니다. 예를 들어, 2024년 7월 인도에 본사를 둔 제약회사 Biological E사는 세계보건기구(WHO)로부터 새로운 경구용 소아마비 백신 2형(nOPV2)을 승인받았습니다. 이 차세대 약독화 경구용 백신은 기존 경구용 소아마비 백신의 문제점, 특히 순환 백신 유래 소아마비 바이러스 2형(cVDPV2)의 집단 발병에 보다 효과적으로 대응할 수 있도록 설계되었습니다. 백신 바이러스가 다시 강독형으로 변이될 수 있는 위험을 감소시켰습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 약독 생 소아마비 백신 시장 : PESTEL 분석(정치·사회·기술·환경·법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 약독 생 소아마비 백신 시장 : 성장률 분석
- 세계의 약독 생 소아마비 백신 시장 규모·성장률 : 실적치, 2019-2024년
- 세계의 약독 생 소아마비 백신 시장 규모·성장률 : 예측치, 2024-2029년, 2034년
- 세계의 약독 생 소아마비 백신 시장 : 총유효과 시장(TAM)
제6장 시장 세분화
- 세계의 약독 생 소아마비 백신 시장 : 백신 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 1가
- 2가
- 3가
- 세계의 약독 생 소아마비 백신 시장 : 투여 경로별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 경구 투여
- 근육내 주사
- 피하주사
- 세계의 약독 생 소아마비 백신 시장 : 연령층별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 유아(0-1세)
- 아동(1-5세)
- 성인(5세 이상)
- 세계의 약독 생 소아마비 백신 시장 : 최종사용자별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 병원
- 클리닉
- 공중위생 기관
- 기타 최종사용자
- 세계의 약독 생 소아마비 백신 시장 : 1가 백신 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- mOPV1 혈청형 1의 경우
- 세계의 약독 생 소아마비 백신 시장 : 2가 백신 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 유형 1
- 유형 3
- 세계의 약독 생 소아마비 백신 시장 : 3가백신 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 폴리오 바이러스 1형
- 폴리오 바이러스 2형
- 폴리오 바이러스 3형
제7장 지역별·국가별 분석
- 세계의 약독 생 소아마비 백신 시장 : 지역별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
- 세계의 약독 생 소아마비 백신 시장 : 국가별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 약독 생 소아마비 백신 시장 : 경쟁 구도
- 약독 생 소아마비 백신 시장 : 기업 개요
- Sanofi Pasteur(개요, 제품 및 서비스, 전략, 재무 분석)
- GlaxoSmithKline plc(개요, 제품 및 서비스, 전략, 재무 분석)
- LG Chem Ltd.(개요, 제품 및 서비스, 전략, 재무 분석)
- Serum Institute of India Pvt. Ltd.(개요, 제품 및 서비스, 전략, 재무 분석)
- Biological E. Limited(개요, 제품 및 서비스, 전략, 재무 분석)
제31장 기타 주요 기업과 혁신적 기업
- Indian Immunologicals Limited
- Sinovac Biotech Ltd.
- Shenzhen Kangtai Biological Products Co. Ltd.
- Vabiotech
- Emergent BioSolutions Inc.
- Valneva SE
- Bio Farma
- PT Bio Farm
- Bilthoven Bio
- Panacea Biotec
- Haffkine Biopharmaceutical
- Panacea Biotec Ltd.
- Zydus Cadila
- Liaoning Cheng Da Biotechnology Co.Ltd
- Bharat Biotech International Limited
제32장 세계 시장 : 경쟁 벤치마킹·대시보드
제33장 주요 기업 인수합병(M&A)
제34장 최근의 시장 동향
제35장 시장 잠재력 높은 나라·부문과 전략
- 약독 생 소아마비 백신 시장 : 최신 기회를 제공하는 국가(2029년)
- 약독 생 소아마비 백신 시장 : 최신 기회를 제공하는 부문(2029년)
- 약독 생 소아마비 백신 시장 : 성장 전략(2029년)
제36장 부록
ksm
The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) containing a weakened form of the poliovirus. This form stimulates a robust immune response without causing disease in healthy individuals. It mimics natural infection, providing long-lasting immunity and helping to prevent the transmission of the virus within communities.
The main types of vaccines in live attenuated polio vaccines include monovalent, bivalent, and trivalent. A monovalent oral polio vaccine (mOPV) is specifically designed to protect against a single type of poliovirus, such as type 1, type 2, or type 3. It can be administered orally, via intramuscular injection, or subcutaneously, depending on the age group infants (0-1 years), children (1-5 years), and adults (above 5 years). This vaccine is used by various end-users, including hospitals, clinics, public health agencies, and other healthcare providers.
The live attenuated polio vaccine market research report is one of a series of new reports from The Business Research Company that provides live attenuated polio vaccine market statistics, including live attenuated polio vaccine industry global market size, regional shares, competitors with a live attenuated polio vaccine market share, detailed live attenuated polio vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated polio vaccine industry. This live attenuated polio vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The live attenuated polio vaccine market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $2.00 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to mass immunization campaigns, concerns over vaccine-derived poliovirus, government immunization programs, increased public awareness and education, and greater accessibility and affordability of vaccines.
The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to improved vaccine stability and shelf life, a resurgence of polio cases in conflict zones, donor fatigue in eradication efforts, the expansion of routine immunization programs, and increased research and development for safer live attenuated vaccine strains. Key trends expected during this period include the emergence of vaccine-derived poliovirus, the development of new oral polio vaccines, technological advancements in vaccine formulations, the integration of digital technologies, and the strengthening of public-private partnerships.
The expansion of immunization programs is expected to significantly contribute to the growth of the live attenuated polio vaccine (LAPV) market in the coming years. Immunization programs are structured efforts by governments, health organizations, and other institutions to distribute vaccines to populations to prevent the spread of infectious diseases. These programs are gaining momentum due to heightened global awareness about the importance of disease prevention, along with strong support from governments, international health organizations, and funding bodies. Immunization programs support LAPVs by ensuring their widespread distribution, safe administration, and high coverage rates, all of which help build herd immunity, prevent virus transmission, and further the goal of global polio eradication. For example, in October 2023, the Centers for Disease Control and Prevention (CDC) reported that global coverage for the first dose of the diphtheria-tetanus-pertussis (DTP) vaccine increased from 86% to 89% between 2021 and 2022. As a result, the expansion of immunization programs is anticipated to drive market growth for live attenuated polio vaccines.
Leading companies in the live attenuated polio vaccine market are focusing on obtaining regulatory approvals to ensure their vaccines meet the necessary safety and efficacy standards set by global health authorities. Regulatory approvals refer to the formal authorization granted by government health agencies or regulatory bodies that permit the marketing, sale, and use of a product, such as a vaccine, within specific regions or countries. For instance, in July 2024, Biological E, an India-based pharmaceutical company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2). This next-generation, live attenuated oral vaccine is designed to better address the challenges posed by traditional oral polio vaccines, especially in combating circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. The nOPV2 is engineered for enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form an issue that has been a concern with older vaccines.
In June 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for approximately $244 million. This acquisition strengthens SK bioscience's leadership in vaccine development and manufacturing, expanding its capabilities and service offerings to improve global health outcomes. The acquisition also aligns with SK bioscience's long-term goals of operational growth and innovation. IDT Biologika, based in Germany, is a contract development and manufacturing organization specializing in viral vaccines, including live attenuated virus vaccines.
Major players in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited.
North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in live attenuated polio vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the live attenuated polio vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The live attenuated polio vaccine market consists of sales of monovalent oral polio vaccine (mOPV), bivalent oral polio vaccine (bOPV), novel oral polio vaccine, and trivalent oral polio vaccine (tOPV). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Live Attenuated Polio Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on live attenuated polio vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for live attenuated polio vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The live attenuated polio vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Vaccine Type: Monovalent; Bivalent; Trivalent
- 2) By Administration Route: Oral Administration; Intramuscular Injection; Subcutaneous Injection
- 3) By Age Group: Infants (0-1 years); Children (1-5 years); Adults (Above 5 years)
- 4) By End-User: Hospitals; Clinics; Public Health Agencies; Other End-Users
- Subsegments:
- 1) Monovalent: mOPV1 For Serotype 1
- 2) Bivalent: Type 1; Type 3
- 3) Trivalent: Poliovirus Type 1; Poliovirus Type 2; Poliovirus Type 3
- Companies Mentioned: Sanofi Pasteur; GlaxoSmithKline plc; LG Chem Ltd.; Serum Institute of India Pvt. Ltd.; Biological E. Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Live Attenuated Polio Vaccine Market Characteristics
3. Live Attenuated Polio Vaccine Market Trends And Strategies
4. Live Attenuated Polio Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Live Attenuated Polio Vaccine Growth Analysis And Strategic Analysis Framework
- 5.1. Global Live Attenuated Polio Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Live Attenuated Polio Vaccine Market Growth Rate Analysis
- 5.4. Global Live Attenuated Polio Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Live Attenuated Polio Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Live Attenuated Polio Vaccine Total Addressable Market (TAM)
6. Live Attenuated Polio Vaccine Market Segmentation
- 6.1. Global Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monovalent
- Bivalent
- Trivalent
- 6.2. Global Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Administration
- Intramuscular Injection
- Subcutaneous Injection
- 6.3. Global Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Infants (0-1 years)
- Children (1-5 years)
- Adults (Above 5 years)
- 6.4. Global Live Attenuated Polio Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Public Health Agencies
- Other End-Users
- 6.5. Global Live Attenuated Polio Vaccine Market, Sub-Segmentation Of Monovalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- mOPV1 For Serotype 1
- 6.6. Global Live Attenuated Polio Vaccine Market, Sub-Segmentation Of Bivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Type 1
- Type 3
- 6.7. Global Live Attenuated Polio Vaccine Market, Sub-Segmentation Of Trivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Poliovirus Type 1
- Poliovirus Type 2
- Poliovirus Type 3
7. Live Attenuated Polio Vaccine Market Regional And Country Analysis
- 7.1. Global Live Attenuated Polio Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Live Attenuated Polio Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Live Attenuated Polio Vaccine Market
- 8.1. Asia-Pacific Live Attenuated Polio Vaccine Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Live Attenuated Polio Vaccine Market
- 9.1. China Live Attenuated Polio Vaccine Market Overview
- 9.2. China Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Live Attenuated Polio Vaccine Market
- 10.1. India Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Live Attenuated Polio Vaccine Market
- 11.1. Japan Live Attenuated Polio Vaccine Market Overview
- 11.2. Japan Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Live Attenuated Polio Vaccine Market
- 12.1. Australia Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Live Attenuated Polio Vaccine Market
- 13.1. Indonesia Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Live Attenuated Polio Vaccine Market
- 14.1. South Korea Live Attenuated Polio Vaccine Market Overview
- 14.2. South Korea Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Live Attenuated Polio Vaccine Market
- 15.1. Western Europe Live Attenuated Polio Vaccine Market Overview
- 15.2. Western Europe Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Live Attenuated Polio Vaccine Market
- 16.1. UK Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Live Attenuated Polio Vaccine Market
- 17.1. Germany Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Live Attenuated Polio Vaccine Market
- 18.1. France Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Live Attenuated Polio Vaccine Market
- 19.1. Italy Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Live Attenuated Polio Vaccine Market
- 20.1. Spain Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Live Attenuated Polio Vaccine Market
- 21.1. Eastern Europe Live Attenuated Polio Vaccine Market Overview
- 21.2. Eastern Europe Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Live Attenuated Polio Vaccine Market
- 22.1. Russia Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Live Attenuated Polio Vaccine Market
- 23.1. North America Live Attenuated Polio Vaccine Market Overview
- 23.2. North America Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Live Attenuated Polio Vaccine Market
- 24.1. USA Live Attenuated Polio Vaccine Market Overview
- 24.2. USA Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Live Attenuated Polio Vaccine Market
- 25.1. Canada Live Attenuated Polio Vaccine Market Overview
- 25.2. Canada Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Live Attenuated Polio Vaccine Market
- 26.1. South America Live Attenuated Polio Vaccine Market Overview
- 26.2. South America Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Live Attenuated Polio Vaccine Market
- 27.1. Brazil Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Live Attenuated Polio Vaccine Market
- 28.1. Middle East Live Attenuated Polio Vaccine Market Overview
- 28.2. Middle East Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Live Attenuated Polio Vaccine Market
- 29.1. Africa Live Attenuated Polio Vaccine Market Overview
- 29.2. Africa Live Attenuated Polio Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Live Attenuated Polio Vaccine Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Live Attenuated Polio Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Live Attenuated Polio Vaccine Market Competitive Landscape And Company Profiles
- 30.1. Live Attenuated Polio Vaccine Market Competitive Landscape
- 30.2. Live Attenuated Polio Vaccine Market Company Profiles
- 30.2.1. Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Biological E. Limited Overview, Products and Services, Strategy and Financial Analysis
31. Live Attenuated Polio Vaccine Market Other Major And Innovative Companies
- 31.1. Indian Immunologicals Limited
- 31.2. Sinovac Biotech Ltd.
- 31.3. Shenzhen Kangtai Biological Products Co. Ltd.
- 31.4. Vabiotech
- 31.5. Emergent BioSolutions Inc.
- 31.6. Valneva SE
- 31.7. Bio Farma
- 31.8. PT Bio Farm
- 31.9. Bilthoven Bio
- 31.10. Panacea Biotec
- 31.11. Haffkine Biopharmaceutical
- 31.12. Panacea Biotec Ltd.
- 31.13. Zydus Cadila
- 31.14. Liaoning Cheng Da Biotechnology Co.Ltd
- 31.15. Bharat Biotech International Limited
32. Global Live Attenuated Polio Vaccine Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Live Attenuated Polio Vaccine Market
34. Recent Developments In The Live Attenuated Polio Vaccine Market
35. Live Attenuated Polio Vaccine Market High Potential Countries, Segments and Strategies
- 35.1 Live Attenuated Polio Vaccine Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Live Attenuated Polio Vaccine Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Live Attenuated Polio Vaccine Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
